Live attenuated measles virus vaccine induces apoptosis and promotes tumor regression in lung cancer

Zhao,Danhua; Chen,Ping; Yang,Huiqiang; Wu,Yonglin; Zeng,Xianwu; Zhao,Yu; Wen,Yanjun; Zhao,Xia; Liu,Xiaolin; Wei,Yuquan; Li,Yuhua

doi:10.3892/or.2012.2109

Live attenuated measles virus vaccine induces apoptosis and promotes tumor regression in lung cancer

Authors:
- Danhua Zhao
- Ping Chen
- Huiqiang Yang
- Yonglin Wu
- Xianwu Zeng
- Yu Zhao
- Yanjun Wen
- Xia Zhao
- Xiaolin Liu
- Yuquan Wei
- Yuhua Li
View Affiliations

Affiliations: State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medical School, Sichuan University, Chengdu 610041, P.R. China, Chengdu Institute of Biological Products, Chengdu 610023, P.R. China, Tiantan Company of Biological Products, Beijing 100024, P.R. China, Department of Arboviral Vaccines and Key Laboratory of the Ministry of Health for Research on Quality and Standardization of Biotech Products, National Institute for Food and Drug Control, Beijing 100050, P.R. China
Published online on: October 29, 2012 https://doi.org/10.3892/or.2012.2109
Pages: 199-204

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Although the treatment of lung carcinoma has improved, at least 65% of patients with this tumor succumb to progressive disease. Measles virus oncolytic therapy has been reported to be effective in reducing tumor burden in immunocompetent or nude mice; however, its potential to reduce tumor burden in lung carcinoma remains to be determined. Herein, we report the potent antitumor effects of a live attenuated measles vaccine virus Hu-191 strain (MV) against lung carcinoma. Immunocompetent C57BL/6 mice bearing Lewis lung carcinoma (LLC) cells were treated with MV (1x104 to 1x106 CCID50/ml) once every other day for 10 days. Our results showed that treatment with MV effectively suppressed tumor growth and significantly prolonged the survival time of tumor-bearing animals. Histological examination revealed that the antitumor effects of MV therapy may result from increased induction of apoptosis, tumor necrosis and elevated lymphocyte infiltration. Our data suggest that MV, one of the widely used vaccines in China, has the ability to inhibit the growth of mouse lung carcinoma and may prove useful in the further exploration of the application of this approach in the treatment of human advanced lung cancer.

View Figures

View References

1	Minna JD, Roth JA and Gazdar AF: Focus on lung cancer. Cancer Cell. 1:49–52. 2002. View Article : Google Scholar
2	Jemal A, Siegel R, Ward E, Murray T, Xu J and Thun MJ: Cancer statistics, 2007. CA Cancer J Clin. 57:43–66. 2007. View Article : Google Scholar
3	Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J and Johnson DH; Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 346:92–98. 2002. View Article : Google Scholar
4	Khuri FR, Herbst RS and Fossella FV: Emerging therapies in non-small-cell lung cancer. Ann Oncol. 12:739–744. 2001. View Article : Google Scholar : PubMed/NCBI
5	Soria JC, Jang SJ, Khuri FR, Hassan K, Liu D, Hong WK and Mao L: Overexpression of cyclin B1 in early-stage non-small cell lung cancer and its clinical implication. Cancer Res. 60:4000–4004. 2000.PubMed/NCBI
6	Vora SA, Daly BD, Blaszkowsky L, McGrath JJ, Bankoff M, Supran S and Dipetrillo TA: High dose radiation therapy and chemotherapy as induction treatment for stage III nonsmall cell lung carcinoma. Cancer. 89:1946–1952. 2000. View Article : Google Scholar : PubMed/NCBI
7	Peng KW, Facteau S, Wegman T, O’Kane D and Russell SJ: Non-invasive in vivo monitoring of trackable viruses expressing soluble marker peptides. Nat Med. 8:527–531. 2002. View Article : Google Scholar : PubMed/NCBI
8	Zhong H, Han B, Tourkova IL, Lokshin A, Rosenbloom A, Shurin MR and Shurin GV: Low-dose paclitaxel prior to intratumoral dendritic cell vaccine modulates intratumoral cytokine network and lung cancer growth. Clin Cancer Res. 13:5455–5462. 2007. View Article : Google Scholar : PubMed/NCBI
9	Erlenhoefer C, Wurzer WJ, Löffler S, Schneider-Schaulies S, ter Meulen V and Schneider-Schaulies J: CD150 (SLAM) is a receptor for measles virus but is not involved in viral contact-mediated proliferation inhibition. J Virol. 75:4499–4505. 2001. View Article : Google Scholar : PubMed/NCBI
10	Tatsuo H, Ono N, Tanaka K and Yanagi Y: SLAM (CDw150) is a cellular receptor for measles virus. Nature. 406:893–897. 2000. View Article : Google Scholar : PubMed/NCBI
11	Hsu EC, Iorio C, Sarangi F, Khine AA and Richardson CD: CDw150 (SLAM) is a receptor for a lymphotropic strain of measles virus and may account for the immunosuppressive properties of this virus. Virology. 279:9–21. 2001. View Article : Google Scholar : PubMed/NCBI
12	Dörig RE, Marcil A, Chopra A and Richardson CD: The human CD46 molecule is a receptor for measles virus (Edmonston strain). Cell. 75:295–305. 1993.PubMed/NCBI
13	Naniche D, Varior-Krishnan G, Cervoni F, Wild TF, Rossi B, Rabourdin-Combe C and Gerlier D: Human membrane cofactor protein (CD46) acts as a cellular receptor for measles virus. J Virol. 67:6025–6032. 1993.PubMed/NCBI
14	Bjørge L, Hakulinen J, Wahlström T, Matre R and Meri S: Complement-regulatory proteins in ovarian malignancies. Int J Cancer. 70:14–25. 1997.
15	Grote D, Russell SJ, Cornu TI, Cattaneo R, Vile R, Poland GA and Fielding AK: Live attenuated measles virus induces regression of human lymphoma xenografts in immunodeficient mice. Blood. 97:3746–3754. 2001. View Article : Google Scholar : PubMed/NCBI
16	Grote D, Cattaneo R and Fielding AK: Neutrophils contribute to the measles virus-induced antitumor effect: enhancement by granulocyte macrophage colony-stimulating factor expression. Cancer Res. 63:6463–6468. 2003.
17	Peng KW, Ahmann GJ, Pham L, Greipp PR, Cattaneo R and Russell SJ: Systemic therapy of myeloma xenografts by an attenuated measles virus. Blood. 98:2002–2007. 2001. View Article : Google Scholar : PubMed/NCBI
18	Dingli D, Peng KW, Harvey ME, Greipp PR, O’Connor MK, Cattaneo R, Morris JC and Russell SJ: Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter. Blood. 103:1641–1646. 2004. View Article : Google Scholar : PubMed/NCBI
19	Phuong LK, Allen C, Peng KW, Giannini C, Greiner S, TenEyck CJ, Mishra PK, Macura SI, Russell SJ and Galanis EC: Use of a vaccine strain of measles virus genetically engineered to produce carcinoembryonic antigen as a novel therapeutic agent against glioblastoma multiforme. Cancer Res. 63:2462–2469. 2003.
20	Peng KW, TenEyck CJ, Galanis E, Kalli KR, Hartmann LC and Russell SJ: Intraperitoneal therapy of ovarian cancer using an engineered measles virus. Cancer Res. 62:4656–4662. 2002.PubMed/NCBI
21	Pumphrey CY, Theus AM, Li S, Parrish RS and Sanderson RD: Neoglycans, carbodiimide-modified glycosaminoglycans: a new class of anticancer agents that inhibit cancer cell proliferation and induce apoptosis. Cancer Res. 62:3722–3728. 2002.PubMed/NCBI
22	Wei YQ, Zhao X, Kariya Y, Fukata H, Teshigawara K and Uchida A: Induction of apoptosis by quercetin: involvement of heat shock protein. Cancer Res. 54:4952–4957. 1994.PubMed/NCBI
23	Gorczyca W, Gong J, Ardelt B, Traganos F and Darzynkiewicz Z: The cell cycle related differences in susceptibility of HL-60 cells to apoptosis induced by various antitumor agents. Cancer Res. 53:3186–3192. 1993.PubMed/NCBI
24	Barry MA, Reynolds JE and Eastman A: Etoposide-induced apoptosis in human HL-60 cells is associated with intracellular acidification. Cancer Res. 53:2349–2357. 1993.PubMed/NCBI
25	Sauter BV, Martinet O, Zhang WJ, Mandeli J and Woo SL: Adenovirus-mediated gene transfer of endostatin in vivo results in high level of transgene expression and inhibition of tumor growth and metastases. Proc Natl Acad Sci USA. 97:4802–4807. 2000. View Article : Google Scholar : PubMed/NCBI
26	Wei YQ, Hang ZB and Liu KF: In situ observation of inflammatory cell-tumor cell interaction in human seminomas (germinomas): light, electron microscopic, and immunohistochemical study. Hum Pathol. 23:421–428. 1992. View Article : Google Scholar : PubMed/NCBI
27	Li G, Tian L, Hou JM, Ding ZY, He QM, Feng P, Wen YJ, Xiao F, Yao B, Zhang R, Peng F, Jiang Y, Luo F, Zhao X, Zhang L, Zhou Q and Wei YQ: Improved therapeutic effectiveness by combining recombinant CXC chemokine ligand 10 with cisplatin in solid tumors. Clin Cancer Res. 11:4217–4224. 2005. View Article : Google Scholar : PubMed/NCBI
28	Xiao F, Wei Y, Yang L, Zhao X, Tian L, Ding Z, Yuan S, Lou Y, Liu F, Wen Y, Li J, Deng H, Kang B, Mao Y, Lei S, He Q, Su J, Lu Y, Niu T, Hou J and Huang MJ: A gene therapy for cancer based on the angiogenesis inhibitor, vasostatin. Gene Ther. 9:1207–1213. 2002. View Article : Google Scholar : PubMed/NCBI
29	Peto R and Peto J: Asymptotically efficient rank invariant test procedures. J R Stat Soc Ser A. 135:185–207. 1972. View Article : Google Scholar
30	Malaguarnera L: Implications of apoptosis regulators in tumorigenesis. Cancer Metastasis Rev. 23:367–387. 2004. View Article : Google Scholar : PubMed/NCBI
31	Liu TC and Kim D: Systemic efficacy with oncolytic virus therapeutics: clinical proof-of-concept and future directions. Cancer Res. 67:429–432. 2007. View Article : Google Scholar : PubMed/NCBI
32	Parato KA, Senger D, Forsyth PA and Bell JC: Recent progress in the battle between oncolytic viruses and tumours. Nat Rev Cancer. 5:965–976. 2005. View Article : Google Scholar : PubMed/NCBI